Information Provided By:
Fly News Breaks for June 17, 2015
ABBV, OSUR
Jun 17, 2015 | 07:33 EDT
Jefferies analyst Brandon Couillard says the 44% year-to-date selloff in shares of OraSure (OSUR) is overdone and thinks now is the time for investors to give the stock another look. Enthusiasm for the company's hepatitis C virus testing collaboration with AbbVie (ABBV) has evaporated, Couillard writes in a research note. However, his sum-of-the-parts analysis suggests 25%-60% share upside potential. The analyst keeps a Buy rating on OraSure with a $9 price target. The diagnostic products company closed yesterday down 3c to $5.65.
News For OSUR;ABBV From the Last 2 Days
There are no results for your query OSUR;ABBV